Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
World J Microbiol Biotechnol ; 30(11): 2861-9, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25108628

RESUMEN

It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 µg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.


Asunto(s)
Antibacterianos/farmacología , Berberina/farmacología , Sinergismo Farmacológico , Ácido Fusídico/farmacología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Carga Bacteriana , Biopelículas/efectos de los fármacos , Humanos , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Staphylococcus aureus Resistente a Meticilina/fisiología , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Infecciones Estafilocócicas/microbiología
2.
Mol Med Rep ; 10(5): 2334-40, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25189202

RESUMEN

To investigate the effects of subminimum inhibitory concentrations of cephalosporins on bacterial biofilm formation, the biofilm production of 52 Escherichia (E.) coli strains was examined following treatment with cephalosporin compounds at 1/4 minimum inhibitory concentrations (MICs). Ceftazidime (CAZ) inhibited biofilm formation in seven isolates, while cefoperazone (CFP) enhanced biofilm formation in 18 isolates. Biofilm formation of E. coli E42 was inhibited by CAZ and induced by CFP. Therefore, using reverse transcription­polymerase chain reaction, the expression of the biofilm­modulating genes of this isolate was investigated. To monitor the production of the autoinducer of quorum sensing in E. coli, autoinducer­2 (AI­2) production was detected by measuring the bioluminescence response of Vibrio harveyi BB170. Antisense oligonucleotides (AS­ODNs) targeting S­ribosylhomocysteine lyase (luxS) inhibited the expression of the luxS gene in E. coli. CAZ at 1/4 MIC reduced luxS mRNA levels and the production of AI­2, whereas CFP at 1/4 MIC had the opposite effect. AS­ODNs targeting luxS significantly decreased the aforementioned inhibitory effects of CAZ and the induction effects of CFP on E. coli biofilm formation. Therefore, biofilm formation by the E. coli clinical isolate E42 was evoked by CFP but attenuated by CAZ at sub­MICs, via a luxS/AI­2­based quorum sensing system.


Asunto(s)
Antibacterianos/farmacología , Proteínas Bacterianas/metabolismo , Biopelículas/efectos de los fármacos , Liasas de Carbono-Azufre/metabolismo , Cefoperazona/farmacología , Ceftazidima/farmacología , Proteínas de Escherichia coli/metabolismo , Escherichia coli/fisiología , Proteínas Bacterianas/genética , Liasas de Carbono-Azufre/genética , Escherichia coli/efectos de los fármacos , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Proteínas de Escherichia coli/genética , Expresión Génica/efectos de los fármacos , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Genes Bacterianos , Humanos , Pruebas de Sensibilidad Microbiana , Percepción de Quorum/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo
3.
FEBS J ; 278(7): 1075-85, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21251230

RESUMEN

Candida infections have become an increasingly significant problem, mainly because of the widespread nature of Candida and drug resistance. There is an urgent need to develop new classes of drugs for the treatment of opportunistic Candida infections, especially in medically complex patients. Previous studies have confirmed that 2-amino-nonyl-6-methoxyl-tetralin muriate (10b) possesses powerful antifungal activity in vitro against Candia albicans. To clarify the underlying action mechanism, an oligonucleotide microarray study was performed in C. albicans SC5314 without and with 10b treatment. The analytical results showed that energy metabolism-related genes, including glycolysis-related genes (PFK1, CDC19 and HXK2), fermentation-related genes (PDC11, ALD5 and ADH1) and respiratory electron transport chain-related genes (CBP3, COR1 and QCR8), were downregulated significantly. Functional analysis revealed that 10b treatment increased the generation of endogenous reactive oxygen species, and decreased mitochondrial membrane potential, ubiquinone-cytochrome c reductase (complex III) activity and intracellular ATP levels in C. albicans SC5314. Also, addition of the antioxidant ascorbic acid reduced the antifungal activity of 10b significantly. These results suggest that mitochondrial aerobic respiration shift and endogenous reactive oxygen species augmentation might contribute to the antifungal activity of 10b against C. albicans. This information may prove to be useful for the development of new strategies to treat Candida infections.


Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candida albicans/genética , Candida albicans/metabolismo , Análisis por Micromatrices/métodos , Especies Reactivas de Oxígeno/metabolismo , Tetrahidronaftalenos/farmacología , Adenosina Trifosfato/metabolismo , Antifúngicos/química , Antifúngicos/uso terapéutico , Candida albicans/citología , Candidiasis/tratamiento farmacológico , Respiración de la Célula/efectos de los fármacos , Farmacorresistencia Fúngica/efectos de los fármacos , Complejo I de Transporte de Electrón/efectos de los fármacos , Complejo I de Transporte de Electrón/fisiología , Complejo III de Transporte de Electrones/efectos de los fármacos , Complejo III de Transporte de Electrones/fisiología , Perfilación de la Expresión Génica , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Estructura Molecular , Tetrahidronaftalenos/química , Tetrahidronaftalenos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA